cmt and me app


by | Oct 1, 2020 | 0 comments

Thursday, October 1 – Saturday, October 31 2020



It is still CMT Awareness month in Europe. The European patients’ groups we worked with on the development of the CMT&Me app are now raising awareness about Charcot-Marie-Tooth across the pond.

CMT is labelled as one of the most common rare diseases, but there are still a lot of unknowns about this condition, both within the medical world and among the general public: CMT month provides an opportunity to raise awareness and better understand the disease.

The CMT&Me community also participates in its own way in this special month!

CMT&Me participants are encouraged to participate in a special charity game.

The CMT&Me study is launching a competition between countries where the study is taking place to help you raise awareness while raising money for charity.

How to participate?

To participate, all you have to do is to update and complete your medical profile in the CMT&Me app between the 1st and 31st October. The principle is simple: for each CMT&Me medical profile which is fully completed in October, $1 will be donated. Each donation will be shared between the 2 major CMT patients advocacy groups, Hereditary Neuropathy Foundation and CMTA.

How to win?

The more profiles completed, the more donations your national association will receive!

The country with the best ratio of medical profile completions per number of participants will be declared the winner (between the USA, Germany, United Kingdom, Italy, Spain and France).

Learn more on this topic

Related Blog Posts

HNF is Reshaping Drug Repurposing for CMT

HNF is Reshaping Drug Repurposing for CMT

HNF has partnered with Rarebase, a public benefit precision medicine company that has screened a large library of FDA approved small molecules to identify candidates for various types of CMT. Their tech-enabled drug discovery platform is called Function™. There are many published discoveries on the genetic cause of many types of CMT, including an understanding of the basic mechanism of disease and potential targets for FDA-approved drug repurposing. It is this understanding that allows HNF and Rarebase to target the genetic root cause of CMT.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news